SCHEMBL20584374

SCHEMBL20584374

COc1cccc(OC)c1-n1c(CCC2CC2)nc(=O)c(-c2nnc(Cn3ccccc3=O)o2)c1O

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 18/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20584662 0.89 APLNR (0.51) APLNR
SCHEMBL20584703 0.88 APLNR (0.62) APLNR
SCHEMBL19001460 0.85 APLNR (0.40) APLNR
SCHEMBL19001438 0.85 APLNR (0.39) APLNR
SCHEMBL20584449 0.84 APLNR (0.49) APLNR
SCHEMBL18991368 0.84 APLNR (0.52) APLNR
SCHEMBL22912191 0.83 APLNR (0.41) APLNR
SCHEMBL28644394 0.83 APLNR (0.39) APLNR
SCHEMBL20584438 0.83 APLNR (0.53) APLNRPTGS2
SCHEMBL20584792 0.82 APLNR (0.42) APLNRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108602813-B Heteroaryl hydroxypyrimidinones as APJ receptor agonists 百时美施贵宝公司 2021-10-29 — — CN claimed
EP-3390400-B1 HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR BRISTOL MYERS SQUIBB CO (US) 2021-01-20 — — EP claimed
US-10669261-B2 Heteroarylhydroxypyrimidinones as agonists of the APJ receptor Bristl-Myers Squibb Company (US) 2020-06-02 — — US claimed
CN-108602813-B Heteroaryl hydroxypyrimidinones as APJ receptor agonists 百时美施贵宝公司 2021-10-29 — — CN disclosed
EP-3390400-B1 HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR BRISTOL MYERS SQUIBB CO (US) 2021-01-20 — — EP disclosed
EP-3390400-B1 HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR BRISTOL MYERS SQUIBB CO (US) 2021-01-20 — — EP disclosed
US-10669261-B2 Heteroarylhydroxypyrimidinones as agonists of the APJ receptor Bristl-Myers Squibb Company (US) 2020-06-02 — — US disclosed
US-10669261-B2 Heteroarylhydroxypyrimidinones as agonists of the APJ receptor Bristl-Myers Squibb Company (US) 2020-06-02 — — US disclosed
US-20180362508-A1 HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR BRISTOL MYERS SQUIBB CO (US) 2018-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669261-B2 Heteroarylhydroxypyrimidinones as agonists of the APJ receptor APLNR, GPBAR1, AGTR1 APLNR 1/4885SMN1; SMN2 4788/4885PTGS2 924/4885
US-20180362508-A1 HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR APLNR, GPBAR1, AGTR1 APLNR 1/4885SMN1; SMN2 4788/4885PTGS2 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback